NASDAQ:DXCM

DexCom Stock Forecast, Price & News

$395.00
-4.49 (-1.12 %)
(As of 04/16/2021 10:46 AM ET)
Add
Compare
Today's Range
$394.01
Now: $395.00
$401.66
50-Day Range
$339.15
MA: $367.22
$405.64
52-Week Range
$295.00
Now: $395.00
$456.23
Volume4,757 shs
Average Volume834,573 shs
Market Capitalization$38.20 billion
P/E Ratio163.22
Dividend YieldN/A
Beta0.86
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
DexCom logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200
Employees5,500
Year Founded1999

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.48 billion
Cash Flow$2.60 per share
Book Value$9.64 per share

Profitability

Net Income$101.10 million

Miscellaneous

Market Cap$38.20 billion
Next Earnings Date4/29/2021 (Confirmed)
OptionableOptionable

Headlines

Dexcom Starts Direct Distribution in the Netherlands
April 7, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

111th out of 2,021 stocks

Surgical & Medical Instruments Industry

13th out of 169 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$395.00
-4.49 (-1.12 %)
(As of 04/16/2021 10:46 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DXCM News and Ratings via Email

Sign-up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DexCom (NASDAQ:DXCM) Frequently Asked Questions

Is DexCom a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DexCom stock.
View analyst ratings for DexCom
or view top-rated stocks.

What stocks does MarketBeat like better than DexCom?

Wall Street analysts have given DexCom a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but DexCom wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is DexCom's next earnings date?

DexCom is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for DexCom
.

How can I listen to DexCom's earnings call?

DexCom will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) issued its earnings results on Thursday, February, 11th. The medical device company reported $0.91 earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of $0.91. The medical device company earned $568.90 million during the quarter, compared to the consensus estimate of $558.41 million. DexCom had a net margin of 12.69% and a trailing twelve-month return on equity of 27.29%.
View DexCom's earnings history
.

How has DexCom's stock price been impacted by Coronavirus (COVID-19)?

DexCom's stock was trading at $252.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DXCM stock has increased by 58.3% and is now trading at $399.49.
View which stocks have been most impacted by COVID-19
.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 11th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.21-2.31 billion, compared to the consensus revenue estimate of $2.33 billion.

What price target have analysts set for DXCM?

17 equities research analysts have issued 1 year target prices for DexCom's stock. Their forecasts range from $350.00 to $500.00. On average, they expect DexCom's stock price to reach $442.75 in the next year. This suggests a possible upside of 10.8% from the stock's current price.
View analysts' price targets for DexCom
or view top-rated stocks among Wall Street analysts.

Who are DexCom's key executives?

DexCom's management team includes the following people:
  • Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 63, Pay $2.09M)
  • Mr. Quentin S. Blackford, CFO & COO (Age 42, Pay $1.17M) (LinkedIn Profile)
  • Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 49, Pay $873.62k)
  • Mr. Andrew K. Balo, Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. (Age 73, Pay $875.97k) (LinkedIn Profile)
  • Mr. Jereme Sylvain, Sr. VP of Fin., Chief Accounting Officer & Corp. Controller (Age 41)
  • Mr. Jacob Steven Leach, Exec. VP & CTO (Age 43) (LinkedIn Profile)
  • Mr. Sean Christensen, Sr. Investor Relations Mang.
  • Mr. Patrick Michael Murphy, Exec. VP & Chief Legal Officer (Age 42) (LinkedIn Profile)
  • Chad Patterson, Sr. VP of Global Marketing
  • Ms. Sadie M. Stern, Exec. VP & Chief HR Officer (Age 46) (LinkedIn Profile)

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom CEO Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among DexCom's employees.

Who are some of DexCom's key competitors?

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), salesforce.com (CRM), ServiceNow (NOW), The Walt Disney (DIS), The Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional investors include Chicago Capital LLC (0.16%), Scout Investments Inc. (0.06%), Retirement Systems of Alabama (0.04%), Royal London Asset Management Ltd. (0.04%), DnB Asset Management AS (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jeffrey Moy, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman and Steven Robert Pacelli.
View institutional ownership trends for DexCom
.

Which institutional investors are selling DexCom stock?

DXCM stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Crossmark Global Holdings Inc., State of Alaska Department of Revenue, Juncture Wealth Strategies LLC, Welch & Forbes LLC, Pacer Advisors Inc., Wolff Wiese Magana LLC, and Gateway Investment Advisers LLC. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Bridgette P Heller, Jacob Steven Leach, Jereme M Sylvain, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Shelly Ramasamy Selvaraj, Steven R Altman, and Steven Robert Pacelli.
View insider buying and selling activity for DexCom
or view top insider-selling stocks.

Which institutional investors are buying DexCom stock?

DXCM stock was bought by a variety of institutional investors in the last quarter, including Scout Investments Inc., Chicago Capital LLC, DnB Asset Management AS, Everence Capital Management Inc., Royal London Asset Management Ltd., Hodges Capital Management Inc., Louisiana State Employees Retirement System, and First Bank & Trust.
View insider buying and selling activity for DexCom
or or view top insider-buying stocks.

How do I buy shares of DexCom?

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $399.49.

How much money does DexCom make?

DexCom has a market capitalization of $38.63 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis.

How many employees does DexCom have?

DexCom employs 5,500 workers across the globe.

Does DexCom have any subsidiaries?

The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.

When was DexCom founded?

DexCom was founded in 1999.

What is DexCom's official website?

The official website for DexCom is www.dexcom.com.

Where are DexCom's headquarters?

DexCom is headquartered at 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121.

How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.